title: Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa.
abstract: Two patients with severe sepsis due to panresistant Pseudomonas aeruginosa, deteriorating despite therapy with colistin and β-lactams, were cured with a high daily dose (25 to 50 mg/kg) of amikacin to obtain a peak/MIC ratio of at least 8 to 10 (MIC = 16 μg/ml). Concomitant use of continuous venovenous hemodiafiltration (CVVHDF) provided no deterioration in renal function after treatment. High dosage of aminoglycosides combined with CVVHDF may represent a valuable therapeutic option for infection due to multiresistant pathogens.
authors.affiliation: Department of Infectious Diseases, Erasme University Hospital, Université Libre de Bruxelles, Route de Lennik 808, Brussels, Belgium.
authors.forename: Brice
authors.initials: B
authors.lastname: Layeux
authors.forename: Fabio Silvio
authors.initials: FS
authors.lastname: Taccone
authors.forename: David
authors.initials: D
authors.lastname: Fagnoul
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Vincent
authors.forename: Frédérique
authors.initials: F
authors.lastname: Jacobs
mesh_terms: D000368:Aged; D000583:Amikacin / Q000627:therapeutic use*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D003404:Creatinine / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity*; D018805:Sepsis / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D000583:Amikacin; D002097:C-Reactive Protein; D003404:Creatinine
references.citation: Int J Antimicrob Agents. 2007 Jun;29(6):630-6
references.pmid: 17306965
references.citation: Clin Infect Dis. 2007 Sep 15;45(6):753-60
references.pmid: 17712761
references.citation: Pharmacotherapy. 2005 Oct;25(10):1353-64
references.pmid: 16185180
references.citation: Antimicrob Agents Chemother. 1999 Jul;43(7):1549-55
references.pmid: 10390201
references.citation: Lancet Infect Dis. 2004 Aug;4(8):519-27
references.pmid: 15288826
references.citation: Ther Drug Monit. 2008 Dec;30(6):674-81
references.pmid: 19057371
references.citation: Curr Opin Pharmacol. 2009 Oct;9(5):558-65
references.pmid: 19748829
references.citation: Crit Care Med. 2009 Apr;37(4):1463-9
references.pmid: 19242341
references.citation: Crit Care. 2010;14(2):R53
references.pmid: 20370907
references.citation: J Infect Dis. 1987 Jan;155(1):93-9
references.pmid: 3540140
references.citation: Clin Pharmacokinet. 1994 Jun;26(6):457-71
references.pmid: 8070219
references.citation: Clin Microbiol Rev. 2009 Oct;22(4):582-610
references.pmid: 19822890
references.citation: Clin Infect Dis. 2005 Oct 15;41(8):1159-66
references.pmid: 16163635